No announcement yet.

Copaxone(R) 15-Year Study In Multiple Sclerosis Patients Demonstrates....

  • Filter
  • Time
  • Show
Clear All
new posts

  • Copaxone(R) 15-Year Study In Multiple Sclerosis Patients Demonstrates....

    Hi, I read about this today.
    Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.

    The 15-year clinical study demonstrated that more than 80 percent of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of patients have not transitioned to secondary progressive MS. Patients who remained in the study over a mean of 15 years showed a reduction in annualized relapse rate (ARR) from baseline as well as minimal increase in Expanded Disability Status Scale (EDSS). On average, the ARR in the ongoing cohort declined from 1.12 ± 0.82 to 0.25 ± 0.34 at the 15-year analysis.
    Get the full report at

    Additionally, the study reinforces the established long-term safety profile associated with Copaxone®. The most common adverse events associated with Copaxone® were local injection-site reactions and immediate post-injection reactions. No other immune-mediated disorders, infections or malignancies were reported.
    Last edited by thumbsup; 03-23-2010, 01:12 PM. - Multiple Sclerosis Symptoms & Guide to Living With Multiple Sclerosis
    Share your MS Story, Win a Free MS Wristband and $500.00 Cash.